Scotiabank analyst Nicholas Yulico raised the firm’s price target on Sabra Health Care to $15 from $14 and keeps a Sector Perform rating on the shares following the release of its Q1 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Medical Properties Stock (NYSE:MPW): Steward Bankruptcy Was Already Priced In
- Sabra Health Care affirms FY24 AFFO view of $1.38-$1.42, consensus $1.40
- Sabra Healthcare Issues Investor Presentation Supplement
- Sabra Health Care reports Q1 FFO 35c , consensus 34c
- Sabra Healthcare Reit (SBRA) Q1 Earnings Cheat Sheet